Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Po-Jung Su

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Chang Gung Medical Journal|November 1, 2011
Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanomaPo-Jung Su, Jen-Shi Chen, Chuang-Chi Liaw, et al.
Biomedical Journal|May 17, 2026
External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapyChung-Hao Ku, Wen-Kuan Huang, Chun-Feng Wu, et al.
Scientific Reports|August 18, 2016
Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing ChemoradiotherapyPo-Jung Su, Min-Hsien Wu, Hung-Ming Wang, et al.
Journal of Cancer|December 1, 2025
Validation of WHO 2017 Classification and Identification of Prognostic Factors in Patients with Pancreatic Neuroendocrine Neoplasms: A Real-World Experience in TaiwanWei-Pang Ho, Wen-Chi Chou, Chia-Hsun Hsieh, et al.
Journal of Pain and Symptom Management|July 17, 2013
Predictive factors for do-not-resuscitate designation among terminally ill cancer patients receiving care from a palliative care consultation serviceChen-Yi Kao, Hung-Ming Wang, Shu-Chuan Tang, et al.
The Prostate|July 1, 2021
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro studyDong-Yi Chen, Po-Jung Su, Lai-Chu See, et al.
International Journal of Cancer|November 8, 2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerHung-Kai Chen, Po-Jung Su, Yan-Lin Wang, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Chang Gung Medical Journal|November 1, 2011
Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanomaPo-Jung Su, Jen-Shi Chen, Chuang-Chi Liaw, et al.
Biomedical Journal|May 17, 2026
External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapyChung-Hao Ku, Wen-Kuan Huang, Chun-Feng Wu, et al.
Scientific Reports|August 18, 2016
Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing ChemoradiotherapyPo-Jung Su, Min-Hsien Wu, Hung-Ming Wang, et al.
Journal of Cancer|December 1, 2025
Validation of WHO 2017 Classification and Identification of Prognostic Factors in Patients with Pancreatic Neuroendocrine Neoplasms: A Real-World Experience in TaiwanWei-Pang Ho, Wen-Chi Chou, Chia-Hsun Hsieh, et al.
Journal of Pain and Symptom Management|July 17, 2013
Predictive factors for do-not-resuscitate designation among terminally ill cancer patients receiving care from a palliative care consultation serviceChen-Yi Kao, Hung-Ming Wang, Shu-Chuan Tang, et al.
The Prostate|July 1, 2021
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro studyDong-Yi Chen, Po-Jung Su, Lai-Chu See, et al.
International Journal of Cancer|November 8, 2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerHung-Kai Chen, Po-Jung Su, Yan-Lin Wang, et al.
Pageof 5